Diabetes mellitus (DM) is a possible risk factor for post-COVID-19 pulmonary fibrosis (PCPF), according to meta-analysis study findings published in BMC Pulmonary Medicine.
PureTech Health has launched a subsidiary company – Celea Therapeutics – with the task of taking an experimental drug for idiopathic pulmonary fibrosis into late-stage clinical testing. Celea has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback